Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia.
Histone H1 is commonly used to assay kinase activity in vitro. As many promising targeted therapies affect kinase activity of specific enzymes involved in cancer transformation, H1 phosphorylation can serve as potential pharmacodynamic marker for drug activity within the cell. In this study we utilized a phosphoproteomic workflow to characterize histone H1 phosphorylation changes associated with two targeted therapies in the Kasumi-1 acute myeloid leukemia cell line. The phosphoproteomic workflow was first validated with standard casein phosphoproteins and then applied to the direct analysis of histone H1 from Kasumi-1 nuclear lysates. Ten H1 phosphorylation sites were identified on the H1 variants, H1.2, H1.3, H1.4, H1.5 and H1.x. LC MS profiling of intact H1s demonstrated global dephosphorylation of H1.5 associated with therapy by the cyclin-dependent kinase inhibitor, flavopiridol and the Heat Shock Protein 90 inhibitor, 17-(Allylamino)-17-demethoxygeldanamycin. In contrast, independent treatments with a nucleotide analog, proteosome inhibitor and histone deacetylase inhibitor did not exhibit decreased H1.5 phosphorylation. The data presented herein demonstrate that potential of histones to assess the cellular response of reagents that have direct and indirect effects on kinase activity that alters histone phosphorylation. As such, this approach may be a highly informative marker for response to targeted therapies influencing histone phosphorylation.
Department of Chemistry, The Ohio State University, Columbus OH, USA.
Liwen
L
Wang
Sean W
SW
Harshman
Shujun
S
Liu
Chen
C
Ren
Hua
H
Xu
Larry
L
Sallans
Michael
M
Grever
John C
JC
Byrd
Guido
G
Marcucci
Michael A
MA
Freitas
D000595:Amino Acid Sequence; D016227:Benzoquinones / Q000494:pharmacology*; D054316:Biomarkers, Pharmacological / Q000032:analysis*; D002364:Caseins / Q000737:chemistry; D005419:Flavonoids / Q000494:pharmacology*; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors*; D006657:Histones / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D047029:Lactams, Macrocyclic / Q000494:pharmacology*; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism*; D008969:Molecular Sequence Data; D058990:Molecular Targeted Therapy; D010748:Phosphopeptides / Q000737:chemistry; D010880:Piperidines / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D016227:Benzoquinones; D054316:Biomarkers, Pharmacological; D002364:Caseins; D005419:Flavonoids; D018841:HSP90 Heat-Shock Proteins; D006657:Histones; D047029:Lactams, Macrocyclic; D010748:Phosphopeptides; D010880:Piperidines; D047428:Protein Kinase Inhibitors; C077990:alvocidib; C112765:tanespimycin